Loading clinical trials...
Loading clinical trials...
Phase 1b Dose-Finding Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 in Patients With Advanced or Metastatic Cancer
Conditions
Interventions
Niraparib
TSR-042
+5 more
Locations
8
United States
GSK Investigational Site
Scottsdale, Arizona, United States
GSK Investigational Site
Encinitas, California, United States
GSK Investigational Site
San Marcos, California, United States
GSK Investigational Site
Sarasota, Florida, United States
GSK Investigational Site
Canton, Ohio, United States
GSK Investigational Site
Cleveland, Ohio, United States
Start Date
October 12, 2017
Primary Completion Date
February 26, 2020
Completion Date
December 11, 2024
Last Updated
November 25, 2025
NCT03206060
NCT05919264
NCT06608446
NCT07541924
NCT07542041
NCT04389632
Lead Sponsor
Tesaro, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions